Global Antivenom Drugs Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Antivenom Drugs Market Insights, Forecast to 2034
Antivenom drugs are used to treat venomous bites and stings, usually preferable in high-toxicity cases. Antivenin, venom antiserum, and antivenom immunoglobulin are the different other names of antivenom drugs. These medications can potentially reverse the effects of snake bites, and generally, an adequate therapeutic dose is injected. Additionally, these medications also help in kidney dialysis, artificial respiration, prosthesis as well as rehabilitation services.
Global Antivenom Drugs market is expected to reach to US$ 1133 million in 2024, with a positive growth of %, compared with US$ 1096 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Antivenom Drugs industry is evaluated to reach US$ 1384.7 million in 2029. The CAGR will be 3.4% during 2024 to 2029.
There are more than 3,000 species of snakes in the world, of which about 250 are prioritized by the WHO because of the potential for serious injury from their venom, spread across 160 countries around the world, the WHO said. Snakebites mainly occur in developing countries in tropical and subtropical regions. Sub-Saharan Africa, tropical Asia, New Guinea, and central and southern America are all high incidence areas of snakebite. In India alone, as many as 2.8 million people are bitten by snakes every year, and more than 46,000 of them die. Rising number of people bitten by snakes is the key driver for the growth of the antivenom market.
Report Covers
This report presents an overview of global Antivenom Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Antivenom Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Bioclone Institute
Pfizer Inc
Merck KGaA
VINS Bioproducts Ltd
BTG International Inc
Incepta Pharma
Bharat Serums and Vaccines Limited
Boston Scientific Corporation
Alomone Labs
Wyeth, LLC
Serum Biotech
Segment by Type
Monovalent
Polyvalent
Hospital
Clinical Laboratory
Field Rescue Station
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Antivenom Drugs plant distribution, commercial date of Antivenom Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Antivenom Drugs introduction, etc. Antivenom Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Antivenom Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Antivenom Drugs market is expected to reach to US$ 1133 million in 2024, with a positive growth of %, compared with US$ 1096 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Antivenom Drugs industry is evaluated to reach US$ 1384.7 million in 2029. The CAGR will be 3.4% during 2024 to 2029.
There are more than 3,000 species of snakes in the world, of which about 250 are prioritized by the WHO because of the potential for serious injury from their venom, spread across 160 countries around the world, the WHO said. Snakebites mainly occur in developing countries in tropical and subtropical regions. Sub-Saharan Africa, tropical Asia, New Guinea, and central and southern America are all high incidence areas of snakebite. In India alone, as many as 2.8 million people are bitten by snakes every year, and more than 46,000 of them die. Rising number of people bitten by snakes is the key driver for the growth of the antivenom market.
Report Covers
This report presents an overview of global Antivenom Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Antivenom Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bioclone Institute
Pfizer Inc
Merck KGaA
VINS Bioproducts Ltd
BTG International Inc
Incepta Pharma
Bharat Serums and Vaccines Limited
Boston Scientific Corporation
Alomone Labs
Wyeth, LLC
Serum Biotech
Segment by Type
Monovalent
Polyvalent
Segment by Application
Hospital
Clinical Laboratory
Field Rescue Station
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Antivenom Drugs plant distribution, commercial date of Antivenom Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Antivenom Drugs introduction, etc. Antivenom Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Antivenom Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices